Scintigraphy with 99m Tc-Phosphonate and 67Gallium in Patients Suspected of Primary Bone Tumors

1982 ◽  
Vol 21 (04) ◽  
pp. 136-139 ◽  
Author(s):  
C.-J. Edeling
Keyword(s):  
Soft Tissue ◽  
Bone Scintigraphy ◽  
Primary Tumor ◽  
Bone Tumors ◽  
Whole Body ◽  
Skeletal Metastases ◽  
Malignant Bone Tumors ◽  
67Ga Scintigraphy ◽  
Primary Bone Tumors ◽  
Primary Bone

Whole-body scintigraphy with both 99mTc-phosphonate and 67Ga was performed on 92 patients suspected of primary bone tumors. In 46 patients with primary malignant bone tumors, scintigraphy with 99mTc-phosphonate disclosed the primary tumor in 44 cases and skeletal metastases in 11, and 67Ga scintigraphy detected the primary tumor in 43 cases, skeletal metastases in 6 cases and soft-tissue metastases in 8 cases. In 25 patients with secondary malignant bone tumors, bone scintigraphy visualized a single lesion in 10 cases and several lesions in 15 cases, and 67Ga scintigraphy detected the primary tumor in 17 cases, skeletal metastases in 17 cases and soft-tissue metastases in 9 cases. In 21 patients with benign bone disease positive uptake of 99mTc-phosphonate was recognized in 19 cases and uptake of 67Ga in 17 cases. It is concluded that bone scintigraphy should be used in patients suspected of primary bone tumors. If malignancy is suspected, 67Ga scintigraphy should be performed in addition.

scholarly journals Primary Bone Tumors: Epidemiologic Comparison of 9200 Patients Treated at Beijing Ji Shui Tan Hospital, Beijing, China, With 10 165 Patients at Mayo Clinic, Rochester, Minnesota

2015 ◽  
Vol 139 (9) ◽  
pp. 1149-1155 ◽  
Author(s):  
Xiaohui Niu ◽  
Hairong Xu ◽  
Carrie Y. Inwards ◽  
Yuan Li ◽  
Yi Ding ◽  
...  
Keyword(s):  
Mayo Clinic ◽  
Bone Tumors ◽  
Age Distribution ◽  
Chinese Patients ◽  
Malignant Bone Tumors ◽  
Primary Bone Tumors ◽  
Male Predominance ◽  
Primary Bone ◽  
Different Populations ◽  
Epidemiologic Characteristics

Context Although primary bone tumors are extremely rare, the literature suggests that there are variations in the epidemiologic characteristics in different populations. The most frequently cited epidemiologic characteristics of primary bone tumors are derived from a large US series (Mayo Clinic), with no comparable study thus far performed in China. Objective To identify any potential epidemiologic differences between Chinese patients and a US series of patients. Design We performed a comparison study between 9200 patients treated at Beijing Ji Shui Tan Hospital (JST) and 10 165 patients treated at Mayo Clinic (MC), Rochester Minnesota. Detailed epidemiologic features were analyzed. Results We found that giant cell tumor and osteosarcoma have significantly higher incidences in the JST than the MC patients (P < .001). However, JST patients had a significantly lower incidence of Ewing sarcoma, chordoma, fibrosarcoma, myeloma, and malignant lymphoma (P < .001). For most benign and malignant bone tumors, the Chinese cohort had a more distinct male predominance than the US cohort. Malignant bone tumors had a monomodal age distribution in the JST patient group, with a bimodal age distribution in the MC cohort. Also, there were was a predilection for tumors of the femur and tibia among the JST patients (P < .001). Conclusions Our data confirm that epidemiologic variations of primary bone tumors exist in different populations. Factors that may contribute to these observed differences are proposed and discussed.

scholarly journals Epidemiology of Osteosarcoma : Single Center Study in Indonesia

2020 ◽  
Vol 13 (1) ◽  
pp. 105-108
Author(s):  
David Kalim ◽  
Andriandi
Keyword(s):  
Soft Tissue ◽  
Bone Disease ◽  
Bone Tumors ◽  
Prevalence Ratio ◽  
Soft Tissue Tumors ◽  
Metastatic Bone Disease ◽  
Primary Bone Tumors ◽  
Musculoskeletal Tumors ◽  
Musculoskeletal Tumour ◽  
Primary Bone

Objective- To assess osteosarcoma epidemiology in Haji Adam Malik General Hospital. Material and Methods- This study is a retrospective descriptive study with a crosssectional approach. Patient with musculoskeletal tumour (especially osteosarcoma) in Haji Adam Malik Hospital from January 2012 to Desember 2017 period, got their age, gender, musculoskeletal tumour type, biopsy result, tumour sites, treatment completion, metastasis and amputation status recorded from their medical record. Result-Primary bone tumors is the most cases and found in 50% of musculoskeletal tumors followed by soft tissue tumors and metastatic bone disease. Male (60%) have slightly higher prevalence than female in (40%). The incidence of primary bone tumors shows osteosarcoma, GCT, and osteochondroma are in the top three with 63%, 13%, and 6% respectively. Specifically for osteosarcoma, male and female have 1.9 : 1 prevalence ratio. The most common sites for osteosarcoma is distal the femur (45%) and proximal tibia (29%). About 63% of patients undergo complete treatment and with 55% recorded with metastasis in the first diagnosis and amputation was performed in 89% of patients. Conclusion- Primary bone tumors dominate the data with 50% for musculoskeletal tumors followed by 31% soft tissue tumors and 19% metastatic bone disease. The incidence of musculoskeletal tumors shows that men are slightly higher than women in 60% and 40%. The incidence of primary bone tumors shows osteosarcoma, giant cell tumor, and osteochondroma are in the top three with 63%, 13%, and 6% respectively.

scholarly journals Role of 18F FDG PET in Differentiating Benign and Malignant Primary Bone Tumors

2015 ◽  
Vol 17 (1) ◽  
pp. 75-83
Author(s):  
Shankar Kumar Dey ◽  
Tanima Biswas
Keyword(s):  
Fdg Pet ◽  
Bone Tumors ◽  
Whole Body ◽  
Benign Tumors ◽  
Vertebral Compression Fractures ◽  
High Accumulation ◽  
Primary Bone Tumors ◽  
Significant Difference ◽  
Primary Bone ◽  
18F Fdg

18F FDG PET is useful in differentiating benign from many kinds of malignant tumors including bone tumors. Many reporters found significant difference of SUV (standardized uptake value) between benign and malignant primary bone tumors. However, some benign bone tumors specially histolytic and Giant cell containing lesions show high accumulation of FDG, which increases false positive rates in FDG-PET. So, consideration of histologic subtypes should be included in analysis of SUV at FDG PET of primary bone tumors. Furthermore, high accumulation of FDG in inflammatory lesions like chronic osteomyelitis and rheumatoid arthritis should also be considered. Dual time-point imaging and determination of retention index provide more help in the differentiation of malignant from benign tumors and is recommended for unclear bone lesions. To differentiate benign from malignant vertebral compression fractures PET showed slightly higher sensitivity over MRI and provide better specificity when both modalities are combined. PET provides opportunity of whole body screening to pick up new lesions and also guide FNAC in case of indeterminate results. DOI: http://dx.doi.org/10.3329/bjnm.v17i1.22495 Bangladesh J. Nuclear Med. 17(1): 75-83, January 2014

Numerical assessment of bone scintigraphy in primary bone tumors and tumor-like conditions.

1978 ◽  
Vol 60 (7) ◽  
pp. 966-969 ◽  
Author(s):  
O Sneppen ◽  
J Heerfordt ◽  
I Dissing ◽  
M Jensen ◽  
J Møller ◽  
...  
Keyword(s):  
Bone Scintigraphy ◽  
Bone Tumors ◽  
Primary Bone Tumors ◽  
Numerical Assessment ◽  
Primary Bone

SYNCHRONOUS COMBINED THERAPY IN ONCOLOGY

2018 ◽  
Vol 64 (4) ◽  
pp. 490-492
Author(s):  
Mikhail Blank ◽  
Olga Blank
Keyword(s):  
Soft Tissue ◽  
Bone Tumors ◽  
High Efficiency ◽  
Combined Therapy ◽  
Soft Tissue Tumors ◽  
Local Effect ◽  
Antitumor Drugs ◽  
Primary Bone Tumors ◽  
Tumor Focus ◽  
Primary Bone

There are presented the main principles and possibilities of simultaneous chemoradiotherapy, including intra-tumoral administration of antitumor drugs in combination with irradiation of primary bone tumors with soft tissue components, metastatic damage of bones, soft tissue tumors as well as superficial tumors and metastases. On the example of 23 patients the high efficiency of synchronous combined therapy is showed. The possibility of using low total doses of ionizing radiation in order to significantly increase the local cytotoxicity of antitumor drugs directly in the tumor focus is substantiated. The proposed variant of synchronous combined therapy makes it possible to obtain a pronounced local effect with minimal systemic toxicity.

scholarly journals Comparison between Benign and Malignant Primary Bone Tumors-A Histopathological Study of 119 Cases

2018 ◽  
Vol 29 (2) ◽  
pp. 74
Author(s):  
Farah Falah Hasan ◽  
Haider Lateef Mohammed
Keyword(s):  
Bone Tumors ◽  
Benign Tumors ◽  
Histopathological Study ◽  
Malignant Bone Tumors ◽  
Female Ratio ◽  
Primary Bone Tumors ◽  
Benign Bone Tumors ◽  
Common Location ◽  
Primary Bone ◽  
The Mean

This is a prospective study done at Al wasity teaching hospital for reconstructive surgeries in Bagdad in a period from November 2014 to April 2017, using a Total of 119 samples of primary bone tumors which were diagnosed both histopathologically and radiologically. The main objectives of this study was to make a comparison between benign and malignant bone tumors. Immunohistochemical staining was done to confirm the diagnosis of primary malignant bone tumors and the proliferative index of them were carefully evaluated. Out of 119 samples of primary bone tumors used in this study ,100 (84%) were benign and borderline(osteoclastoma) and 19(16%) were malignant, the mean age for benign tumors was lower than the mean age for primary malignant one and both frequently present in the 2nd decade of life, male to female ratio for benign bone tumors was 3\2 and 8.5\1 for primary malignant one, femure was the most common location for benign bone tumors while tibia was the most common bone affected by primary malignant bone tumors. the study also showed that the most common benign bone tumors were osteochondromas(67%) and most common primary malignant bone tumors were osteosarcomas(52.63%),thus this study rise a conclusion that in general, primary bone tumors were mainly benign, occurred predominantly in the second decade of life with a male preponderance

scholarly journals Proximal Femur Versus Acetabular Extra-articular Resection of the Hip Joint for Primary Malignant Bone Tumors : A Retrospective Comparative Review of 33 Cases

2021 ◽  
Author(s):  
Victor Housset ◽  
Philippe Anract ◽  
Antoine Babinet ◽  
Guillaume Auberger ◽  
David Biau
Keyword(s):  
Hip Joint ◽  
Proximal Femur ◽  
Bone Tumors ◽  
Malignant Bone Tumors ◽  
Primary Bone Tumors ◽  
Comparative Review ◽  
Primary Bone ◽  
The Mean ◽  
Cumulative Probabilities

Abstract Introduction Extra-articular resection (EAR) of the hip joint is prone to significant complications and morbidity. Thus, this study evaluates the cumulative incidences and main reasons of reoperation following EAR of primary bone tumors of the hip to determine whether the outcomes are different between EAR of the pelvis and that of the proximal femur. Patients and methods Thirty-three patients presented with a PMBT of the proximal femur or pelvis were included in this study. Among all PMBTs, 58% originated from the pelvis and 42% were from the proximal femur. Twenty patients had chondrosarcomas (61%), 10 had osteosarcomas (30%), and 3 had sarcomas of another histological subtype (9%). Results The mean follow-up was of 76 months (range: 24–220 months). The cumulative probabilities of revision for any reason was 52% (95% confidence interval [CI]: 30%–70%) five years after surgery. The five-year cumulative probabilities of revision were 13% (95% CI: 4%–27%), 24% (95% CI: 10%–42%) and 34% (95% CI: 14%–56%) for mechanical, infectious and tumoral reasons, respectively. The five-year cumulative probabilities of revision for any reason were 78% (95% CI: 37%–94%) and 14% (95% CI: 2%–38%) for the pelvis and proximal femur, respectively ( p = 0.004). Posterior column preservation was significantly associated with more mechanical complications even after adjusting for the resection site ( p = 0.043). Conclusion Half of patients undergoing EAR of the hip joint for PMBT of the proximal femur or acetabulum will require another operation. EAR of the pelvis is associated with significantly worse outcome than EAR of the proximal femur.

scholarly journals Malignant bone tumors in Pediatrics. Five year experience in a pediatric referral center

2016 ◽  
Vol 64 (3) ◽  
pp. 403
Author(s):  
Gisela Barros ◽  
Angela Maria Trujillo ◽  
Lina Jaramillo ◽  
Francy Helena Ortiz ◽  
Agustin Dario Contreras
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Bone Tumors ◽  
Ewing’S Sarcoma ◽  
Surgical Intervention ◽  
Ewing's Sarcoma ◽  
Survival Rates ◽  
Pediatric Hospital ◽  
Malignant Bone Tumors ◽  
Primary Bone Tumors ◽  
Primary Bone

Background: Osteosarcoma (OS) and Ewing’s Sarcoma (ES) are the two most common malignant bone tumors in children. A retrospective review of the records of children diagnosed in a pediatric hospital over a five year period (2008-2013) was performed.Objective: To present the experiences acquired during the treatment of these types of tumors and to compare the results obtained with those reported in the literature.Methodology: The database of the Oncology and Pathology Service of Fundación Hospital de la Misericordia (HOMI) was reviewed to identify patients with primary bone tumors referred for histopathology analysis.Results: 22 patients were diagnosed with OS, with a mean age of 11.9 years. 96% of cases were located in the lower extremities. All patients received neoadjuvant chemotherapy and 86% underwent surgical treatment; 13% survived. 15 patients were diagnosed with ES, with a mean age of 12.4 years. 67% of cases were located in flat bones, 53% of patients had metastasis when diagnosed, and all received neoadjuvant chemotherapy. 40% of patients received surgical intervention and 20% received radiotherapy. Survival at the completion of the reseearch was 33%.Conclusions: Cure and survival rates are lower than those reported in the literature despite efforts to improve treatments.Keywords: Osteosarcoma; Ewing’s Sarcoma; Disease Progression; Recurrence; Neoplasm Metastasis (MeSH).

scholarly journals RANKL/RANK/osteoprotegerin system as novel therapeutic target in the treatment of primary bone tumors and osteolytic metastases

2004 ◽  
Vol 12 (2) ◽  
pp. 112-114 ◽  
Author(s):  
Zlatibor Andjelkovic ◽  
Vuka Katic ◽  
Dragan Mihailovic ◽  
Aleksandar Petrovic ◽  
Ivan Bubanovic
Keyword(s):  
Bone Tumors ◽  
Osteoclast Differentiation ◽  
Treatment Strategies ◽  
Osteoclast Formation ◽  
Skeletal Metastases ◽  
Bone Homeostasis ◽  
Primary Bone Tumors ◽  
Receptor Activator ◽  
Primary Bone ◽  
Nf Kappab

Primary bone tumors and cancers that metastasize to bone require osteoclastic activity to release tumor-supportive growth factors from bone tissue. A number of systemic and locally acting factors are known to influence osteoclast formation, fusion, activation, and survival. Recently, two critical extracellular regulators of osteoclast differentiation and activation have been identified: receptor activator of nuclear factor (NF-kappaB) ligand (RANKL) and osteoprotegerin (OPG). RANKL is a tumor necrosis factor (TNF)-related cytokine that stimulates osteoclast differentiation from hematopoietic precursor cells and activation of mature osteoclasts. RANKL activates its specific receptor, receptor activator of NF- kappaB (RANK), located on osteoclasts, chondrocytes and dendritic cells. Binding of the RANK ligand to its receptor and osteoclastogenesis are prevented by osteoprotegerin, a decoy receptor produced by osteoblasts and marrow stromal cells. The balance between RANKL and OPG is of major importance in bone homeostasis. Disorders of the RANKL/RANK/OPG system have been linked to several human diseases, including primary bone tumors skeletal metastases, and hypercalcemia of malignancy. The discovery and characterization of RANKL, RANK and OPG and subsequent studies have changed the concepts of bone metabolism and may form the basis of innovative therapeutic strategies. Novel treatment strategies for bone tumors are emerging based on blockade of the RANKL/RANK interaction. The advantage of these strategies is their potential to selectively target tumor cells. Combining these new strategies with currently available treatments such as chemotherapy and radiation therapy is under investigation, with promising results.

Sign in / Sign up

Export Citation Format

Share Document